Efficacy and Safety of Sustained Release Donepezil High Dose versus Immediate Release Donepezil Standard Dose in Japanese Patients with Severe Alzheimer’s Disease: A Randomized, Double-Blind Trial

Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: a pooled area under the curve analysis

(2015) Alireza Atri et al.   Alzheimers Research & Therapy

EFFICACY AND TOLERABILITY OF DONEPEZIL 23MG/D VERSUS DONEPEZIL 10MG/D IN PATIENTS WITH MODERATE TO SEVERE AD IN AN ASIAN POPULATION: STUDY 326 SUBANALYSIS

(2014) Han Seol-Heui et al.   Alzheimers & Dementia

Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer’s disease: analysis of effects of baseline features on treatment response

(2013) Marwan Sabbagh et al.   BMC Geriatrics

Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease

(2012) Robert Howard et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease

(2011) Martin Farlow et al.   BMC Neurology

Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study

(2010) Martin R. Farlow et al.   CLINICAL THERAPEUTICS

Donepezil Treatment of Patients with Severe Alzheimer’s Disease in a Japanese Population: Results from a 24-Week, Double-Blind, Placebo-Controlled, Randomized Trial

(2008) Akira Homma et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS